Esketamine: A Possible Adjunctive Therapy for Treatment Resistant Depression

References

1. 1.↵
   1. Reif A,
   2. Bitter I,
   3. Buyze J

   , ESCAPE-TRD Investigatorset al. Esketamine nasal spray versus quetiapine for treatment-resistant depression. N Engl J Med 2023;389:1298–309.

   OpenUrlCrossRefPubMed
2. 2.↵
   World Health Organization. Depression and other common mental disorders: global health estimates. Geneva: World Health Organization; 2017. License: CC-BY-NC-SA 3.0 IGO.
3. 3.↵
   1. Gaynes BN,
   2. Lux L,
   3. Gartlehner G,
   4. et al

   . Defining treatment-resistant depression. Depress Anxiety 2020;37:134–45.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Li CT

   . Overview of treatment-resistant depression. Prog Brain Res 2023;278:1–23.1.

   OpenUrlPubMed
5. 5.↵
   1. Little A

   . Treatment-resistant depression. Am Fam Physician 2009;80:167–72.

   OpenUrlPubMedWeb of Science
6. 6.↵
   1. Greenberg PE,
   2. Fournier AA,
   3. Sisitsky T,
   4. Pike CT,
   5. Kessler RC

   . The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry 2015;76:155–62.

   OpenUrlCrossRefPubMed
7. 7.
   Depression in adults: treatment and management. London: National Institute for Health and Care Excellence (NICE); June 29, 2022.
8. 8.↵
   1. Ruberto VL,
   2. Jha MK,
   3. Murrough JW

   . Pharmacological treatments for patients with treatment-resistant depression. Pharmaceuticals (Basel) 2020;13:116.

   OpenUrlPubMed
9. 9.↵
   1. Smith P,
   2. Castelli G

   . The Priority Updates from the Research Literature (PURLs) Methodology. J Am Board Fam Med 2024;37:799–802.

   OpenUrlFREE Full Text